ArticleProbiotics and antimicrobial proteins2026
A Functional Limosilactobacillus reuteri ZY18 Strain: Probiotic Properties and Associated Anti-inflammatory Responses Against ETEC K88 Infection.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Limosilactobacillus reuteri (L. reuteri) has probiotic advantages such as suppressing pathogenic bacteria, balancing the gut microbiota, regulating immunity, and having anti-inflammatory and antioxidant properties. This study explored its potential antibacterial and anti-inflammatory properties, isolating the bacterium from healthy pig feces. L. reuteri ZY18 was chosen due to its superior acid production, tolerance, and antibacterial characteristics. In vitro, the ZY18 strain had a survival rate of 46.00% in simulated gastric juice and efficiently inhibited enterotoxigenic Escherichia coli K88 (ETEC K88), with an inhibition zone measuring 1.90 cm. In a mouse model challenged with ETEC K88, it demonstrated anti-inflammatory and antioxidant activities, as well as improved intestinal mechanical barrier integrity. Notably, the protective effects of ZY18 on the immune barrier were closely associated with the modulation of T helper 17 (Th17) cells and interleukin-17 (IL-17). These findings suggest that ZY18 has high antibacterial and anti-inflammatory capabilities, providing an associative basis that probiotic-based microbial products could be exploited as alternative therapeutic options for ETEC K88-related disorders.
Indexed as
Identifiers
42400750What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.